The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.

Bradley J. Monk; Rachel N. Grisham; Christian Marth; Susana N. Banerjee; Felix Hilpert; Robert L. Coleman; Eric Pujade-Lauraine; Sandro Pignata; Mansoor Raza Mirza; Amit M. Oza; Josep M. del Campo; Martin Klaus Oehler; Adam James; Janna Christy-Bittel; Emma Barrett; Adam P. Boyd; Ignace Vergote

Journal Article

The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.

Monk B
Grisham R
Marth C
et al.

Journal of Clinical Oncology (2015) 33(15_suppl) TPS5610-TPS5610

DOI: 10.1200/jco.2015.33.15_suppl.tps5610

N/ACitations

9Readers

Get full text

Abstract

TPS5610 Background: Low-grade serous (LGS) carcinomas of the ovary, fallopian tube and primary peritoneum are a unique subset of serous carcinomas for which current therapies (chemotherapy, hormona...

Cite

CITATION STYLE

APA

Monk, B. J., Grisham, R. N., Marth, C., Banerjee, S. N., Hilpert, F., Coleman, R. L., … Vergote, I. (2015). The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. Journal of Clinical Oncology, 33(15_suppl), TPS5610–TPS5610. https://doi.org/10.1200/jco.2015.33.15_suppl.tps5610

Abstract

Cite

Register to see more suggestions